Cell line · CVCL_1338
Papers38
1 to 20 of 38
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| The role of ATP synthase subunit e (ATP5I) in mediating the metabolic and antiproliferative effects of metformin in cancer cells. | Elife | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Diet-Induced Phospholipid Remodeling Dictates Ferroptosis Sensitivity and Tumorigenesis in the Pancreas. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| GLIS3 marks a neural-like progenitor cell state that drives metastasis in pancreatic ductal adenocarcinoma. | Cell Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Overcoming Adaptive Resistance to KRASG12D Blockade in Pancreatic Cancer through Vertical Pathway Inhibition. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Integrated spatial morpho-transcriptomics predicts functional traits in pancreatic cancer. | Sci Adv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| CRISPR-Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| A RAS(ON) Multi-Selective Inhibitor Combination Therapy Triggers Long-term Tumor Control through Senescence-Associated Tumor-Immune Equilibrium in Pancreatic Ductal Adenocarcinoma. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Leucine aminopeptidase LyLAP enables lysosomal degradation of membrane proteins. | Science | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Stiff extracellular matrix activates the transcription factor ATF5 to promote the proliferation of cancer cells. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Enhancing PDAC therapy: Decitabine-olaparib synergy targets KRAS-dependent tumors. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting Pancreatic Cancer Cell Stemness by Blocking Fibronectin-Binding Integrins on Cancer-Associated Fibroblasts. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Minimally invasive determination of pancreatic ductal adenocarcinoma (PDAC) subtype by means of circulating cell-free RNA. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting KRAS-mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Inactivation of HIPK2 attenuates KRASG12D activity and prevents pancreatic tumorigenesis. | J Exp Clin Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| The role of DPYD and the effects of DPYD suppressor luteolin combined with 5-FU in pancreatic cancer. | Cancer Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Non-canonical functions of SNAIL drive context-specific cancer progression. | Nat Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Systematic Interrogation of Tumor Cell Resistance to Chimeric Antigen Receptor T-cell Therapy in Pancreatic Cancer. | Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1338/papers